Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALKS |
---|---|---|
09:32 ET | 5819 | 24.51 |
09:34 ET | 1191 | 24.54 |
09:36 ET | 602 | 24.515 |
09:38 ET | 1422 | 24.455 |
09:39 ET | 1700 | 24.52 |
09:41 ET | 1477 | 24.5 |
09:43 ET | 2685 | 24.57 |
09:45 ET | 1616 | 24.58 |
09:48 ET | 700 | 24.585 |
09:50 ET | 4429 | 24.67 |
09:52 ET | 1289 | 24.68 |
09:54 ET | 900 | 24.73 |
09:56 ET | 720 | 24.695 |
09:57 ET | 700 | 24.7 |
09:59 ET | 1600 | 24.69 |
10:01 ET | 4746 | 24.685 |
10:03 ET | 700 | 24.66 |
10:06 ET | 2351 | 24.64 |
10:08 ET | 4417 | 24.71 |
10:10 ET | 2915 | 24.73 |
10:12 ET | 100 | 24.74 |
10:14 ET | 900 | 24.73 |
10:15 ET | 3045 | 24.76 |
10:17 ET | 200 | 24.73 |
10:19 ET | 700 | 24.7 |
10:21 ET | 1434 | 24.68 |
10:24 ET | 1979 | 24.69 |
10:26 ET | 100 | 24.7 |
10:28 ET | 988 | 24.68 |
10:30 ET | 200 | 24.685 |
10:32 ET | 1503 | 24.69 |
10:33 ET | 1405 | 24.71 |
10:35 ET | 1300 | 24.71 |
10:37 ET | 1400 | 24.68 |
10:39 ET | 300 | 24.68 |
10:42 ET | 787 | 24.675 |
10:44 ET | 4350 | 24.67 |
10:46 ET | 500 | 24.68 |
10:48 ET | 2337 | 24.67 |
10:50 ET | 1311 | 24.65 |
10:51 ET | 600 | 24.65 |
10:53 ET | 948 | 24.61 |
10:55 ET | 1158 | 24.6 |
10:57 ET | 300 | 24.6075 |
11:00 ET | 3538 | 24.575 |
11:02 ET | 200 | 24.57 |
11:04 ET | 100 | 24.57 |
11:06 ET | 1736 | 24.5942 |
11:08 ET | 1940 | 24.59 |
11:09 ET | 2034 | 24.6 |
11:11 ET | 1100 | 24.57 |
11:13 ET | 1642 | 24.57 |
11:15 ET | 820 | 24.56 |
11:18 ET | 4807 | 24.57 |
11:20 ET | 400 | 24.57 |
11:22 ET | 400 | 24.57 |
11:24 ET | 2250 | 24.58 |
11:26 ET | 700 | 24.6 |
11:27 ET | 3551 | 24.59 |
11:29 ET | 1252 | 24.59 |
11:31 ET | 1400 | 24.58 |
11:33 ET | 1350 | 24.58 |
11:36 ET | 1500 | 24.56 |
11:38 ET | 5129 | 24.56 |
11:40 ET | 550 | 24.57 |
11:42 ET | 2281 | 24.58 |
11:44 ET | 2021 | 24.58 |
11:45 ET | 1100 | 24.57 |
11:47 ET | 5273 | 24.56 |
11:49 ET | 350 | 24.56 |
11:51 ET | 750 | 24.55 |
11:54 ET | 3085 | 24.55 |
11:56 ET | 1700 | 24.54 |
11:58 ET | 1840 | 24.54 |
12:00 ET | 200 | 24.545 |
12:02 ET | 6928 | 24.59 |
12:03 ET | 2700 | 24.56 |
12:05 ET | 398 | 24.56 |
12:07 ET | 200 | 24.56 |
12:09 ET | 600 | 24.57 |
12:12 ET | 3085 | 24.57 |
12:14 ET | 2436 | 24.57 |
12:16 ET | 3425 | 24.56 |
12:18 ET | 1708 | 24.565 |
12:20 ET | 500 | 24.565 |
12:21 ET | 2208 | 24.59 |
12:23 ET | 3939 | 24.57 |
12:25 ET | 1157 | 24.525 |
12:27 ET | 700 | 24.51 |
12:30 ET | 900 | 24.49 |
12:32 ET | 2050 | 24.45 |
12:34 ET | 300 | 24.45 |
12:36 ET | 3021 | 24.45 |
12:38 ET | 1510 | 24.47 |
12:39 ET | 5102 | 24.45 |
12:41 ET | 870 | 24.465 |
12:43 ET | 1600 | 24.46 |
12:45 ET | 2466 | 24.43 |
12:50 ET | 100 | 24.445 |
12:52 ET | 1500 | 24.45 |
12:54 ET | 500 | 24.455 |
12:56 ET | 3546 | 24.445 |
12:57 ET | 2242 | 24.47 |
12:59 ET | 1326 | 24.47 |
01:01 ET | 200 | 24.47 |
01:03 ET | 3344 | 24.48 |
01:06 ET | 300 | 24.47 |
01:10 ET | 2880 | 24.47 |
01:12 ET | 100 | 24.47 |
01:14 ET | 1519 | 24.46 |
01:15 ET | 100 | 24.455 |
01:17 ET | 4107 | 24.445 |
01:19 ET | 1762 | 24.45 |
01:21 ET | 1906 | 24.45 |
01:24 ET | 673 | 24.46 |
01:26 ET | 1184 | 24.4599 |
01:28 ET | 3065 | 24.455 |
01:30 ET | 4580 | 24.49 |
01:32 ET | 4069 | 24.4825 |
01:35 ET | 400 | 24.48 |
01:37 ET | 300 | 24.475 |
01:39 ET | 3582 | 24.45 |
01:42 ET | 5487 | 24.45 |
01:44 ET | 893 | 24.47 |
01:46 ET | 2949 | 24.43 |
01:48 ET | 400 | 24.44 |
01:50 ET | 3638 | 24.445 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alkermes Plc | 4.1B | 7.0x | --- |
Exelixis Inc | 6.5B | 34.9x | -21.77% |
PTC Therapeutics Inc | 2.7B | -4.5x | --- |
P3 Health Partners Inc | 167.5M | -0.9x | --- |
Novavax Inc | 2.0B | -4.1x | --- |
Qiagen NV | 9.0B | 27.3x | +12.66% |
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.1B |
---|---|
Revenue (TTM) | $1.7B |
Shares Outstanding | 169.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $3.50 |
Book Value | $7.20 |
P/E Ratio | 7.0x |
Price/Sales (TTM) | 2.4 |
Price/Cash Flow (TTM) | 6.2x |
Operating Margin | 29.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.